(Reuters) - The company also announced a $1 billion deal with Pfizer Inc. to help develop and sell Bristol's promising apixaban drug to prevent blood clots.
The drugmaker's shares fell 3.3 percent after analysts speculated its tie-up with Pfizer could deter other drugmakers from making an attempt to acquire Bristol.
Read more at Reuters.com Market News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment